{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-057578","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.857688+00:00","generated_at":"2026-06-07T12:51:05.856721+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Roivant closes $7.1B sale of Telavant to Roche; retains 75% ownership prior to closing","bullets":["Total upfront cash consideration of approximately $7.1 billion paid to Telavant equity holders.","Roivant owned 75% of Telavant on an as-converted basis before the transaction closed.","Additional $150 million cash milestone payable upon initiation of a Phase 3 ulcerative colitis trial.","Telavant holds US and Japan rights to TL1A antibody RVT-3101 for IBD and Crohn's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-057578","json":"https://secwatch.observer/filing/0001140361-23-057578.json","markdown":"https://secwatch.observer/filing/0001140361-23-057578.md","text":"https://secwatch.observer/filing/0001140361-23-057578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/0001140361-23-057578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/ef20016626_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:51:05.856721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26ef81efb37a3e19760432b9a0c0613cdbb69fae","claim":"Roivant Sciences Ltd. completed a disposition involving Roche Holdings, Inc. for approximately $7.1 billion in cash (closed 2023-12-14).","evidence_excerpt":"On December 14, 2023, pursuant to the Purchase Agreement, the Buyer completed the Transaction for total consideration of approximately $7.1 billion in cash at the closing of the Transaction (the “Closing”), paid or to be paid to all of Telavant’s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant prior to the Closing.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/0001140361-23-057578-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Roche Holdings, Inc."},{"label":"Consideration","value":"approximately $7.1 billion in cash"},{"label":"Closing","value":"2023-12-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}